We came across a bullish thesis on Nurix Therapeutics, Inc. on Clinical Catalysts’s Substack. In this article, we will summarize the bulls’ thesis on NRIX. Nurix Therapeutics, Inc.’s share was trading at $17.59 as of January 29th.
Copyright: dolgachov / 123RF Stock Photo
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory...
